I'm not sure if the ease of distribution is enough of a differentiator imo. TLX gozellix kit appears to have a good shelf life which nullifies this. Efficacy in the guise of sensitivity for a diagnostic will be the main attractor for clinicians wanting to use cu6, if cu64 ends up with a much higher sensitivity.
- Forums
- ASX - By Stock
- Ann: First patient imaged in Phase III AMPLIFY trial
CU6
clarity pharmaceuticals ltd
Add to My Watchlist
3.24%
!
$2.23

I'm not sure if the ease of distribution is enough of a...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$2.23 |
Change
0.070(3.24%) |
Mkt cap ! $716.6M |
Open | High | Low | Value | Volume |
$2.15 | $2.29 | $2.13 | $4.198M | 1.899M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 4477 | $2.22 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$2.23 | 9998 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 10000 | 2.250 |
3 | 2854 | 2.230 |
2 | 2480 | 2.210 |
2 | 27000 | 2.200 |
1 | 20000 | 2.190 |
Price($) | Vol. | No. |
---|---|---|
2.120 | 5684 | 1 |
2.230 | 780 | 1 |
2.240 | 10 | 1 |
2.250 | 5833 | 3 |
2.260 | 392 | 1 |
Last trade - 16.10pm 16/06/2025 (20 minute delay) ? |
Featured News
CU6 (ASX) Chart |